Merck's KEYTRUDA receives positive CHMP opinions for new administration route and indication

Merck's KEYTRUDA received two positive opinions from the European Medicines Agency's CHMP, recommending approval for a new subcutaneous administration and an expanded indication for resectable head and neck squamous cell carcinoma, with final EU decisions anticipated in Q4 2025. These approvals, alongside a pending U.S. FDA review for the subcutaneous form, portend significant market expansion and enhanced patient convenience for the blockbuster oncology drug. While the company recently surpassed Q2 2025 EPS expectations, it reported a slight revenue shortfall and saw a Berenberg downgrade to "Hold" citing Keytruda patent concerns, even as it proceeds with a $10 billion acquisition of Verona Pharma and advances other clinical programs.

Analysis

Merck (MRK) has received two significant positive opinions from the European Medicines Agency's CHMP for its blockbuster drug, KEYTRUDA, signaling potential market expansion and enhanced competitive positioning. The first recommendation is for a new subcutaneous (SC) formulation, which would drastically reduce administration time and broaden treatment settings, supported by trial data showing comparable pharmacokinetic exposure to the intravenous version. The second recommends approval for an expanded use in treating certain head and neck squamous cell carcinoma (LA-HNSCC) patients, based on a Phase 3 trial that demonstrated a statistically significant improvement in event-free survival. Final decisions from the European Commission are expected in Q4 2025, with a similar SC application under review by the U.S. FDA, targeting a September 2025 decision. These pipeline advancements are set against a mixed financial and analytical backdrop. While Merck surpassed Q2 2025 EPS expectations at $2.13, it reported a marginal revenue shortfall of $15.81 billion against a $15.87 billion forecast. Furthermore, Berenberg downgraded the stock to Hold with a price target cut to $90, citing concerns over future "Keytruda patent issues." The company maintains strong fundamentals, including a 77.41% gross profit margin and a 3.97% dividend yield at a P/E of 12.55, and is actively pursuing growth through a $10 billion acquisition of Verona Pharma and other clinical trials.

Key Decisions for Investors

• Investors should view the positive CHMP opinions for KEYTRUDA's subcutaneous formulation and expanded HNSCC indication as key potential catalysts, with regulatory decision dates in Q4 2025 (EU) and September 2025 (US) being critical inflection points to watch.
• The bullish pipeline news must be weighed against notable headwinds, including the Berenberg downgrade that specifically flags "Keytruda patent issues," a slight Q2 revenue miss, and the integration risk of the $10 billion Verona Pharma acquisition.
• For value and income-focused investors, Merck's P/E ratio of 12.55 and dividend yield of 3.97% may present an attractive entry point, though upside potential remains contingent on successful pipeline execution to mitigate long-term patent risks.